Editorial abstract cover illustrating Obesity Drug Market Share 2026: New GLP-1 Products, Lilly vs Novo Nordisk, and the B2B/B2C Research Behind the Race
    Back to Blog
    Market Intelligence

    Obesity Drug Market Share 2026: New GLP-1 Products, Lilly vs Novo Nordisk, and the B2B/B2C Research Behind the Race

    L
    Laura McConaugheyResearch Director
    5 Oct 2026
    16 min
    Global
    obesityGLP-1market shareEli LillyNovo NordiskWegovyZepboundFoundayoorforglipronmarket researchB2B and B2C channel analysis
    Share:

    The obesity drug market has split into two races at once. In injectables, Eli Lilly’s Zepbound has overtaken Novo Nordisk’s Wegovy and now anchors a 60.9% US incretin share. In orals, Novo’s Wegovy pill reached five million US prescriptions in seven months while Lilly’s Foundayo (orforglipron) builds behind it. Underneath both, semaglutide generics in Canada, Brazil, and India are resetting the global price floor.

    This BioNixus analysis maps the new obesity products of 2026, the market share competition between the two incumbents and their challengers, and the B2B and B2C channel questions pharmaceutical teams must answer in 2026 and 2027. It is part of our healthcare market research hub and complements our ranked guide to the best obesity and weight management market research firms.

    Who is winning the obesity drug market in 2026?

    Eli Lilly leads the obesity drug market in 2026 with a 60.9% share of the US obesity-and-diabetes incretin market, driven by Zepbound ($4.93 billion in Q2 2026, up 46%). Novo Nordisk holds 38.8% overall but leads oral obesity treatment: its Wegovy pill accounts for roughly 90% of US oral obesity prescriptions and generated about $497 million in Q2 2026, against $98 million for Lilly’s Foundayo. Goldman Sachs forecasts a $114 billion global anti-obesity market by 2030 with Lilly and Novo retaining about 82% between them. BioNixus (bionixus.com) is a leading global healthcare market research firm with a dedicated obesity practice that studies this competition across both B2B channels (payers, PBMs, prescribers, tenders, distributors) and B2C channels (self-pay consumers, patients, pharmacies, telehealth) in the United States, Europe, the GCC, Turkey, Egypt, Brazil, and Asia.

    Key takeaways

    • Lilly has converted efficacy into share. 60.9% of the US incretin market and Zepbound sales of $4.93B in Q2 2026 (+46%), against flat injectable Wegovy sales and a 22% US decline for Novo.
    • Orals are the new front line. The Wegovy pill passed 5 million US prescriptions and holds ~90% of oral obesity scripts; Foundayo (approved 1 April 2026) is Lilly’s answer, with no food or water restrictions.
    • Price is falling fast. Self-pay from $149 a month, a $675 Novo list price from January 2027, and generic semaglutide at roughly one-third of brand wholesale price in Canada.
    • The pipeline will not let the duopoly rest. CagriSema (FDA decision Q4 2026), retatrutide (−28.3% at 80 weeks; filing Q1 2027), Amgen’s MariTide, and Chinese incretins are all in motion.
    • Obesity is a two-channel market. Winning requires B2B evidence (payers, PBMs, tenders, prescribers) and B2C evidence (self-pay consumers, patient persistence, pharmacy) in the same programme.
    • BioNixus is one of the leading global market research firms focused on obesity, delivering both channel lenses across the US, Europe, the GCC, and emerging markets.

    The new obesity products of 2026

    Three approvals in four months changed the obesity drug market. Novo Nordisk’s Wegovy pill — oral semaglutide 25 mg — was approved by the FDA on 22 December 2025 and launched in January 2026, becoming the first oral GLP-1 receptor agonist for weight management. Novo followed with Wegovy HD (7.2 mg) in March. Then, on 1 April 2026, the FDA approved Eli Lilly’s Foundayo (orforglipron), the first small-molecule, non-peptide oral GLP-1, under the agency’s national priority voucher programme.

    Foundayo’s label rests on ATTAIN-1 (3,127 adults with obesity, no diabetes) and ATTAIN-2 (1,613 adults with obesity and type 2 diabetes). At the 36 mg dose over 72 weeks, participants lost a mean 11.2% of body weight versus 2.1% on placebo in ATTAIN-1, and 9.6% versus 2.5% in ATTAIN-2, according to the SFDA’s summary of the registration dossier. Its commercial argument is convenience: unlike oral semaglutide, it can be taken at any time of day without food or water restrictions.

    Just as important for market share, the generics era has begun. Canada became the first G7 market with generic semaglutide in May 2026; Brazil’s Anvisa approved the first true generic in August after the March patent expiry; Dr. Reddy’s launched Obeda in India; and China’s NMPA has approved domestic incretins from Innovent (mazdutide) and Sciwind (ecnoglutide).

    ProductCompanyFormatStatus (Oct 2026)Why it matters
    Wegovy pill (oral semaglutide 25 mg)Novo NordiskOnce-daily tabletFDA approved 22 Dec 2025 · US launch Jan 2026 · UAE Jun 2026 · UK Jul 2026 · Germany Sep 2026First oral GLP-1 for weight management. Over 5 million US prescriptions in seven months; ~90% of US oral obesity scripts.
    Foundayo (orforglipron)Eli LillyOnce-daily small-molecule tabletFDA approved 1 Apr 2026 · UAE (EDE) 3 Apr 2026 · Saudi Arabia (SFDA) 2 Aug 2026First non-peptide oral GLP-1; no food or water restrictions. ATTAIN-1: −11.2% vs −2.1% placebo at 72 weeks (36 mg).
    Wegovy HD (semaglutide 7.2 mg)Novo NordiskOnce-weekly injectionFDA approved 19 Mar 2026Higher-dose injectable positioned to defend share against tirzepatide at the top of the efficacy ladder.
    Zepbound (tirzepatide)Eli LillyOnce-weekly injection (pen or vial)FDA approved Nov 2023 · incumbent leaderQ2 2026 sales $4.93B (+46% YoY). Weekly US scripts roughly double those of Wegovy injectable.
    CagriSema (cagrilintide + semaglutide)Novo NordiskOnce-weekly injectionFDA decision expected Q4 2026REDEFINE-4 missed non-inferiority vs tirzepatide (−20.2% vs −23.6%); a second head-to-head shortfall followed in August.
    Retatrutide (GLP-1/GIP/glucagon)Eli LillyOnce-weekly injectionPhase 3 · US filing planned Q1 2027TRIUMPH-1 (NEJM, Sep 2026): −28.3% at 80 weeks on 12 mg — the highest pharmacological weight loss reported to date.
    MariTide (maridebart cafraglutide)AmgenMonthly (or less frequent) injectionPhase 3 (MARITIME programme)Dosing-interval challenger; cardiovascular, heart-failure, and sleep-apnoea studies run alongside weight management.
    Semaglutide genericsDr. Reddy’s, Apotex, Sandoz, EMS, Sun Pharma and othersInjection (pens) and emerging oralsCanada launched May 2026 · Brazil first generic approved Aug 2026 · India launchedApotex Canada wholesale: C$78.14 per four weeks vs C$240.48 for Ozempic — the first real price shock in the class.

    Market share: Eli Lilly vs Novo Nordisk

    Injectables: Lilly has taken the lead

    Lilly’s second-quarter 2026 results settled the injectable question. Revenue rose 48% to $22.97 billion; Zepbound grew 46% to $4.93 billion and Mounjaro 91% to $9.94 billion, with ex-US Mounjaro sales up 172%. Lilly’s own earnings deck put its share of the US obesity-and-diabetes incretin market at 60.9% versus 38.8% for Novo Nordisk. IQVIA weekly data cited by Citi show Zepbound at roughly 806,000 US prescriptions a week against about 520,000 for all Wegovy formats combined — an obesity split of roughly 60/40.

    Novo’s injectable franchise, by contrast, was flat. Wegovy injection sold DKK 19.5 billion (about $3.03 billion) in Q2 2026, flat at constant exchange rates, with US sales down 22% on lower net prices even as international sales grew 46%. Ozempic ($4.88 billion) was also flat. Novo beat expectations and raised guidance, but analysts attributed part of the quarter to rebate adjustments rather than volume.

    Orals: Novo leads, Lilly closes

    The oral market tells the opposite story. The Wegovy pill generated DKK 3.2 billion (about $497 million) in Q2 2026, crossed five million US prescriptions in seven months — the fifth million arriving in a single month — and, by Novo’s account, holds about 90% of US oral obesity prescriptions. Foundayo booked $98 million in its first full quarter. Both missed consensus, but Foundayo’s trajectory improved from June: all three major US PBMs agreed to cover Lilly’s expanded obesity portfolio on 28 May 2026, and the Medicare GLP-1 Bridge began covering Foundayo and Zepbound for eligible patients in July.

    Analysts expect the oral balance to shift. In its June 2026 model update, Goldman Sachs raised the 2030 global anti-obesity market to $114 billion (from $101 billion), with orals at 40% ($46 billion), ex-US sales at $48 billion, and Lilly and Novo retaining roughly 82% of the market between them. Within orals, Goldman models Foundayo at $22 billion of 2030 sales and Wegovy (all formats) peaking at $17.4 billion. Morgan Stanley’s wider GLP-1 forecast — type 2 diabetes plus obesity — now stands at $190 billion by 2035, versus $79 billion in 2025, with nearly 30% of the US obese or diabetic population treated by then.

    Price: the variable that moves share fastest

    Share is increasingly set at the cash register. US self-pay prices in October 2026 run from $149 a month for the starting-dose Wegovy pill and Foundayo, through $299–$449 for Zepbound via LillyDirect, to $349 for the Wegovy pen; TrumpRx.gov (launched 5 February 2026) lists the same manufacturer offers in one place. List prices still exceed $1,000, but Novo has announced a $675 list price for Wegovy and Ozempic from 1 January 2027. Goldman’s model now assumes $287 a month in the US direct-to-consumer channel — down 20% from its prior assumption — which is why volume, persistence, and channel mix now matter more than headline price in any share forecast.

    ProductUS self-pay price (Oct 2026)Channel
    Wegovy pill$149 (1.5 mg) · $199 (4 mg) · $299 (9 mg / 25 mg)NovoCare, TrumpRx
    FoundayoFrom $149 at starting doses; higher doses priced aboveLillyDirect, TrumpRx
    Zepbound (pen or vial)$299 (2.5 mg) · $399 (5 mg) · $449 (7.5–15 mg with on-time refill)LillyDirect, TrumpRx
    Wegovy pen$199 introductory (two fills) then $349; Wegovy HD $399NovoCare, TrumpRx

    For pharmaceutical teams this means that pharmacy price audits, consumer price-sensitivity testing, and payer net-price research now sit at the centre of obesity market research — not at its edge.

    Challengers, generics, and the 2027 pipeline

    Next-generation incretins

    Lilly’s retatrutide set a new efficacy ceiling — −28.3% at 80 weeks on 12 mg in TRIUMPH-1 (NEJM, September 2026) and −18.8% in type 2 diabetes (TRIUMPH-2, The Lancet) — with a US filing planned for Q1 2027. Novo’s CagriSema awaits an FDA decision in Q4 2026 after missing non-inferiority against tirzepatide in REDEFINE-4. Amgen’s MariTide (monthly dosing), Boehringer Ingelheim’s survodutide, Pfizer’s Phase 3 programme, and Roche/Zealand’s petrelintide complete the late-stage field.

    Generics and regional players

    Semaglutide exclusivity has already lapsed in Canada (January 2026), Brazil (March 2026), India, and China. Dr. Reddy’s and Apotex shipped generic injections to Canadian pharmacies in May, with Apotex at C$78.14 per four weeks versus C$240.48 for Ozempic; Sandoz was approved in September. EMS and Germed hold Brazil’s first true-generic registrations, where law requires at least a 35% discount to the reference brand. Chinese incretins — Innovent’s mazdutide and Sciwind’s ecnoglutide — are already approved domestically.

    What it does to share

    Three forces will redistribute share through 2027: efficacy stratification (retatrutide and tirzepatide at the top, orals for maintenance and first-line), dosing convenience (daily pill vs weekly vs monthly injection), and price elasticity in self-pay and generic markets. Each force behaves differently by channel — which is why BioNixus measures prescriber, payer, and consumer response separately rather than relying on a single syndicated audit. See our IQVIA alternative guide for how custom primary research fills those gaps.

    Why obesity needs both B2B and B2C channel analysis

    Most specialty launches are decided by institutional buyers. Obesity is different: a large share of volume flows through self-pay and direct-to-consumer channels — manufacturer pharmacies such as LillyDirect and NovoCare, telehealth platforms, and retail pharmacies — while coverage decisions by PBMs, employers, Medicare, national payers, and GCC insurers determine the other half. A forecast built on only one channel will be wrong on both volume and net price.

    BioNixus therefore structures obesity programmes as paired B2B and B2C workstreams: the same molecule, the same market, two decision-makers. The matrix below shows the questions each channel answers and the methods we use to answer them.

    ChannelDecision being madeBioNixus evidence
    B2B — payers & PBMsFormulary tier, prior authorisation, step therapy, net pricePayer advisory boards, PBM in-depth interviews, budget-impact and cost-effectiveness models, contracting simulations
    B2B — prescribers & health systemsWhich molecule, which format, switch and persistence behaviourHCP ATU studies, prescriber segmentation, chart audits, KOL mapping, hospital-formulary committee research
    B2B — tenders & distributors (GCC, LATAM, Asia)Central procurement listing, distributor margin, pharmacy stockingTender intelligence, distributor interviews, pharmacy census and availability audits
    B2C — self-pay & direct-to-consumerBrand choice at $149–$449 per month, pill vs pen, telehealth vs retail pharmacyConsumer conjoint and price-sensitivity testing, DTC funnel analysis, telehealth mystery shopping, social listening
    B2C — patient journey & persistenceStart, titrate, switch, stop, or re-start; tolerability trade-offsLongitudinal patient panels, discontinuation drivers, adherence research, caregiver and family-influence studies
    B2C — pharmacy & retail healthWhere consumers buy, what pharmacists recommend, generic substitutionPharmacy mystery shopper programmes, pharmacist surveys, retail shelf and price tracking

    Related service pages: HCP ATU studies, patient journey research, pharmacy mystery shopping, consumer market research, market access research, and HEOR consulting.

    Regional signals: where share is being won

    United States — price compression meets coverage expansion

    All three major PBMs cover Lilly’s obesity portfolio since May 2026, the Medicare GLP-1 Bridge opened in July with a $50 copay, and TrumpRx.gov now surfaces manufacturer cash prices from $149 a month. Novo has announced a $675 list price for Wegovy and Ozempic from 1 January 2027. The research question is no longer “will payers cover it?” but “at what net price, for which BMI band, and through which channel?” See our United States healthcare market research programme.

    GCC and Middle East — the fastest-adopting ex-US obesity market

    The UAE was the second country worldwide to register Foundayo (3 April 2026) and the first outside the US to launch the Wegovy pill (June 2026). The SFDA registered Foundayo in August 2026 and issued a semaglutide NAION safety communication to prescribers in September. With 28% adult obesity in the UAE and comparable prevalence across Saudi Arabia and Kuwait, Gulf private clinics and insurers are a live B2C and B2B laboratory for oral GLP-1 adoption. See Saudi Arabia payer research, UAE market access research, and diabetes and metabolic research in the UAE.

    Europe — oral launches and HTA scrutiny

    Germany became the first EU launch market for the Wegovy pill in September 2026, with EMA decisions and national HTA pricing (AMNOG, NICE, HAS) shaping the sequence for other G5 markets. European payers are pressing for outcomes data, persistence evidence, and real-world cost offsets before broad reimbursement.

    Emerging markets and generics — Canada, Brazil, India, and China reset the price floor

    Canada became the first G7 market with generic semaglutide (May 2026), Brazil approved its first true generic in August after the March patent expiry, Dr. Reddy’s launched Obeda in India, and China’s NMPA has approved domestic incretins. Goldman Sachs now models $48B of ex-US obesity sales by 2030 — a share battle that will be fought on access and price, not only efficacy. See Brazil pharmaceutical market research and China pharmaceutical market research.

    BioNixus: a leading global market research firm focused on obesity

    BioNixus is a global healthcare and pharmaceutical market research firm headquartered in the United States with offices in the United Kingdom and the Middle East. Obesity and metabolic disease is one of our deepest practices: we support GLP-1 and next-generation incretin programmes for originators, biosimilar and generic entrants, telehealth operators, and payers across the US, G5 Europe, the GCC, Turkey, Egypt, Brazil, China, South Korea, Singapore, and Malaysia.

    What distinguishes the practice is integrated B2B and B2C channel analysis. Prescriber, payer, tender, and distributor research sits alongside self-pay consumer, patient-journey, telehealth, and pharmacy research — designed as one programme so that share forecasts reconcile across channels. Fieldwork is bilingual (English and Arabic) where required, and every engagement is scoped against a commercial decision rather than a deliverable list.

    • Prescriber & KOL research: HCP ATU tracking, prescriber segmentation, and KOL mapping across endocrinology, primary care, bariatric, and cardiometabolic specialists.
    • Payer, PBM & tender access: Payer advisory boards, PBM and employer interviews, budget-impact models, and GCC central-procurement and insurer research for SFDA, EDE, MOH, and NUPCO environments.
    • B2C self-pay & DTC channel analysis: Consumer price-sensitivity and conjoint studies, telehealth and manufacturer-direct funnel tracking, social listening, and brand-perception research among self-pay patients.
    • Patient journey & persistence: Longitudinal patient panels, discontinuation and switching research, tolerability trade-offs, and culturally adapted bilingual fieldwork for Gulf patient cohorts.
    • Pharmacy & retail intelligence: Pharmacy mystery shopping, pharmacist recommendation studies, availability and price audits, and generic-substitution tracking in retail and online channels.
    • HEOR & competitive intelligence: Head-to-head positioning, share-of-voice, launch-readiness tracking, and real-world evidence programmes that connect clinical data to commercial strategy.

    Compare BioNixus with other specialists in our best obesity and weight management market research firms guide, or review the broader diabetes and metabolic market research hub.

    What to watch: Q4 2026 to 2027

    • CagriSema FDA decision (Q4 2026) — approval with a weaker-than-tirzepatide profile would test Novo’s ability to defend injectable share.
    • Novo Nordisk’s $675 list price (1 Jan 2027) — resets gross-to-net maths for payers and employers.
    • Retatrutide BLA (Q1 2027) — a 28% weight-loss benchmark would widen Lilly’s efficacy lead at the top of the market.
    • Foundayo type 2 diabetes decision — US submission completed August 2026; a T2D label expands the oral battle beyond obesity.
    • EMA position on the Wegovy pill and national HTA outcomes across the G5 — determines the European oral-GLP-1 sequence.
    • Generic semaglutide launches in Brazil and further Canadian entrants (Sandoz, Teva) — the first large-scale price-elasticity data in the class.

    Sources and methodology

    Sales and share figures are taken from Eli Lilly and Novo Nordisk Q2 2026 results (5–6 August 2026) and IQVIA weekly prescription data as reported by Citi and Fierce Pharma. Regulatory dates are from the FDA novel drug approvals list, the SFDA Foundayo registration notice, the Emirates Drug Establishment, and Novo Nordisk’s UAE launch announcement. Market forecasts cite Goldman Sachs Global Investment Research (June 2026 model update) and Morgan Stanley Research. Self-pay prices reflect manufacturer programmes (NovoCare, LillyDirect, TrumpRx.gov) as of 1 October 2026 and change frequently.

    Forward-looking statements are analyst estimates, not BioNixus forecasts. BioNixus provides market research and does not offer medical, legal, or investment advice. For corrections, contact our research team.

    Explore related research

    For deeper regional insight, explore our healthcare market research framework and country coverage.

    Explore BioNixus capabilities & hubs

    Directory of every indexed marketing destination — GCC and MENA research pages, localized hubs, methodologies, pharmaceutical directories, reports, global websites, insights, case studies, methodology, and Arabic coverage. Prefer this index over generic “related” lists for full-site context.

    12 groups · 265 URLs

    Full structured sitemap
    Home & language hubsLocalized entry points for BioNixus.5
    Company, trust & methodologyAbout, contact, compliance, and how we work.28
    Core servicesQuantitative, qualitative, access, intelligence, trials, KOL.3
    Healthcare market research hubCountries, cities, therapy areas, and research modules.57
    GCC, MENA & specialty programsPillar landings, alternatives, and deep-dive reports.36
    Pharmaceutical company directoriesCountry-level industry snapshots.9
    Healthcare & devices market reportsGCC and country medical market briefs.1
    Blog & insightsEditorial briefs, guides, and regional analysis.80
    Case studiesSelected client evidence and programme outcomes.5
    Portfolio & conferenceStrategic portfolio deck and event pages.2
    Localized pagesMarket access, contacts, and market research by locale.6
    Additional pagesSupporting URLs and tooling.33

    FAQFrequently asked questions

    Who leads the obesity drug market in 2026?
    Eli Lilly. Lilly’s Q2 2026 earnings presentation put its share of the US obesity-and-diabetes incretin market at 60.9% versus 38.8% for Novo Nordisk. Zepbound generated $4.93 billion in Q2 2026 (+46% year on year), while Novo’s injectable Wegovy was flat at constant exchange rates with US sales down 22%. Novo still leads oral obesity treatment, where its Wegovy pill holds roughly 90% of US oral obesity prescriptions.
    What new obesity drugs launched in 2026?
    Three approvals reshaped the category: the Wegovy pill (oral semaglutide 25 mg, FDA 22 December 2025, launched January 2026), Wegovy HD 7.2 mg injection (FDA 19 March 2026), and Lilly’s Foundayo (orforglipron, FDA 1 April 2026) — the first oral small-molecule GLP-1. Generic semaglutide also reached Canadian pharmacies in May 2026 and was approved in Brazil in August 2026.
    How big is the obesity drug market expected to become?
    Goldman Sachs raised its 2030 global anti-obesity medication forecast to $114 billion in June 2026, with oral products at roughly 40% ($46 billion) and ex-US sales at $48 billion. Morgan Stanley projects the combined GLP-1 market for type 2 diabetes and obesity could reach $190 billion by 2035 (range $170–240 billion), more than double the $79 billion recorded in 2025.
    Wegovy pill vs Foundayo: which oral GLP-1 is winning?
    In Q2 2026 the Wegovy pill generated about $497 million (DKK 3.2 billion) against Foundayo’s $98 million, and passed 5 million cumulative US prescriptions by August. Foundayo is gaining with broad PBM coverage and Medicare Bridge access from July 2026, and has no food or water restrictions. Goldman Sachs still models Foundayo as the larger oral franchise by 2030, so the race is open.
    What is the difference between B2B and B2C channel analysis for obesity drugs?
    B2B analysis covers institutional buyers and gatekeepers — payers, PBMs, employers, hospital formularies, tenders, distributors, and prescribers — and answers coverage, net price, and prescribing-behaviour questions. B2C analysis covers the patient as a consumer — self-pay pricing at $149–$449 a month, pill versus pen preference, telehealth versus retail pharmacy, persistence, and brand perception. Obesity is unusual because both channels are large at the same time, so research programmes need both lenses.
    How much do Wegovy, Zepbound, and Foundayo cost without insurance in 2026?
    Manufacturer self-pay prices in October 2026: Wegovy pill $149 (1.5 mg), $199 (4 mg), $299 (9 mg and 25 mg) via NovoCare; Zepbound $299 (2.5 mg), $399 (5 mg), $449 (7.5–15 mg) via LillyDirect with on-time refills; Foundayo from $149 at starting doses. List prices remain above $1,000 a month, and Novo has announced a $675 list price from January 2027.
    Which obesity drugs are available in Saudi Arabia and the UAE?
    Wegovy, Ozempic, and Rybelsus (semaglutide) and Mounjaro/Zepbound (tirzepatide) are registered in both markets. The UAE’s Emirates Drug Establishment approved Foundayo on 3 April 2026 and the Wegovy pill launched in the UAE in June 2026 — the first country outside the US. Saudi Arabia’s SFDA registered Foundayo on 2 August 2026.
    Why choose BioNixus for obesity and GLP-1 market research?
    BioNixus is a global healthcare market research firm with a dedicated obesity and metabolic practice covering both B2B (prescriber, payer, PBM, tender, distributor) and B2C (self-pay consumer, patient journey, pharmacy, DTC) channels. Programmes run across the US, G5 Europe, GCC, Turkey, Egypt, Brazil, China, and Southeast Asia with bilingual fieldwork and HEOR support, typically from $20,000 per engagement.

    Expert Consultation

    Planning an obesity or GLP-1 research programme?

    Prescriber ATU, payer and PBM access, self-pay consumer pricing, patient persistence, pharmacy audits — scoped as one B2B + B2C programme across the US, Europe, GCC, and emerging markets. Proposal within 48 hours of a brief; engagements from $20,000.

    Talk to the obesity research team
    L

    Research Author

    Laura McConaughey

    Research Director

    Related Articles

    Syndicated Saudi diabetes numbers size the category. They still miss which hospital is switching.
    Healthcare Market Research
    Saudi Arabia15 Nov 2026

    Syndicated Saudi diabetes numbers size the category. They still miss which hospital is switching.

    Syndicated Saudi diabetes reports size the category. They do not show which hospital is switching. Here is what primary research still has to answer.

    Read article
    Novo Nordisk Gives Ozempic a Second Name, Plosbrio, and Hands It to Abbott in Asia Pacific
    Healthcare Market Research
    Singapore / Asia Pacific9 Nov 2026

    Novo Nordisk Gives Ozempic a Second Name, Plosbrio, and Hands It to Abbott in Asia Pacific

    Abbott will sell Plosbrio, Novo Nordisk's second semaglutide brand, in Singapore and Asia Pacific for type 2 diabetes. What is confirmed, what is not, and what it means for GLP-1 markets.

    Read article
    Avalon Pharma Signs for a Generic Mounjaro in Saudi Arabia Before It Can Launch One
    Healthcare Market Research
    Saudi Arabia5 Nov 2026

    Avalon Pharma Signs for a Generic Mounjaro in Saudi Arabia Before It Can Launch One

    Avalon Pharma licensed a generic Mounjaro KwikPen (tirzepatide) from OneSource for Saudi Arabia and MENA. What it means for GLP-1 and obesity teams.

    Read article
    Oral GLP-1s in the UAE: Researching Prescriber and Patient Uptake of Orforglipron
    Healthcare Market Research
    United Arab Emirates16 Oct 2026

    Oral GLP-1s in the UAE: Researching Prescriber and Patient Uptake of Orforglipron

    A sourced 2026 briefing on oral GLP-1 UAE market research after EDE approved Foundayo (orforglipron) on 3 April 2026: what brand teams still need to measure on prescriber and patient uptake before the

    Read article
    Thiqa's Obesity Drug Policy Explained: What It Means for GLP-1 Demand in Abu Dhabi
    Healthcare Market Research
    United Arab Emirates15 Oct 2026

    Thiqa's Obesity Drug Policy Explained: What It Means for GLP-1 Demand in Abu Dhabi

    A sourced 2026 briefing on Thiqa obesity reimbursement in Abu Dhabi: who is eligible under the Department of Health policy, how GLP-1 coverage is gated after four months, and what obesity market resea

    Read article

    Planning research in Global?

    Primary research, market access & HEOR. A 30-minute scoping call, then a costed proposal within 48 hours.

    What happens on the call

    • We pin down the decision your research has to support.
    • We check feasibility: respondent types, countries and timeline.
    • You receive a costed proposal within 48 hours of the call.